Hepatology

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, Altimmune, and UnitedHealth and Encourages Investors to Contact the Firm

Retrieved on: 
木曜日, 5月 30, 2024
Insurance, Semaglutide, EQIX, UNH, UnitedHealth Group, Partnership, The Wall Street Journal, MASH, Hepatology, Optum, Kerrisdale, News, Obesity, CSI, Change Healthcare, Guggenheim Partners, OTC, Defendant, NASH, Policy, Acquisition, P.C, Weight loss, DOJ, Bloomberg, Disclosure, Complaint

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR

Key Points: 
  • For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
    Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
  • The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
  • On January 6, 2021, UnitedHealth announced an agreement to acquire Change Healthcare (“Change”) and integrate it into its Optum business.
  • As a result of this disclosure, the price of UnitedHealth stock declined by $27 per share, erasing nearly $25 billion in shareholder value.

Intercept Announces New Data to be Presented at the European Association for the Study of the Liver (EASL) Congress 2024

Retrieved on: 
水曜日, 5月 29, 2024
Patient, Primary biliary cholangitis, Hepatology, Ursodeoxycholic acid, EASL, Congress, Intercept Pharmaceuticals, Cirrhosis, Senior, PBC, Research, Abstract, Liver disease, Intercept, Biomarker, Alkaline phosphatase, Head, Therapy, Bezafibrate, Medical imaging

MORRISTOWN, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced nine abstracts related to primary biliary cholangitis (PBC) and alcohol-related liver disease will be presented at EASL Congress 2024.

Key Points: 
  • MORRISTOWN, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced nine abstracts related to primary biliary cholangitis (PBC) and alcohol-related liver disease will be presented at EASL Congress 2024.
  • The congress will be held from June 5-8 in Milan, Italy.
  • “We are thrilled to present our latest research in PBC at this year’s EASL Congress,” said Sangeeta Sawhney, Senior Vice President and Head of U.S. Research & Development at Intercept.
  • A full list of sessions at EASL Congress 2024 is available at www.easlcongress.eu .

Bluejay Therapeutics Receives Positive Opinion on Orphan Designation from the European Medicines Agency for BJT-778 for the Treatment of Chronic Hepatitis D

Retrieved on: 
水曜日, 5月 29, 2024
European Medicines Agency, Conditional sentence, Patient, Therapy, EMA, HDV, Hepatology, SAN, CHD, Pharmaceutical industry

SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for orphan designation for BJT-778 for the treatment of chronic hepatitis D (CHD).

Key Points: 
  • SAN MATEO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Bluejay Therapeutics, a private clinical-stage biopharmaceutical company focused on viral and liver diseases with unmet medical needs, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s application for orphan designation for BJT-778 for the treatment of chronic hepatitis D (CHD).
  • “We are delighted that the EMA has issued a positive opinion for orphan designation for BJT-778.
  • This recognition underscores the urgent need for new treatment options for people living with this devastating chronic infection,” said Keting Chu, Founder and CEO of Bluejay Therapeutics.
  • “We are eager to accelerate the development of BJT-778 and make it available to patients as soon as possible.

ALTIMMUNE, INC. (NASDAQ: ALT) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Altimmune, Inc. Investors of Upcoming Deadline

Retrieved on: 
火曜日, 5月 28, 2024
Semaglutide, Hepatology, Action Replay, Kerrisdale, News, Obesity, Advertising, Defendant, Court, Weight loss, District court, Complaint, Security (finance)

If you purchased or acquired Altimmune securities, and/or would like to discuss your legal rights and options please visit Altimmune, Inc.

Key Points: 
  • If you purchased or acquired Altimmune securities, and/or would like to discuss your legal rights and options please visit Altimmune, Inc.
  • If you wish to serve as lead plaintiff, you must move the Court no later than July 5, 2024.
  • Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients.
  • The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines – ALT

Retrieved on: 
火曜日, 5月 28, 2024
Semaglutide, Partnership, Southern Division, Hepatology, Kerrisdale, News, Obesity, Prior, Person, Ext, Guggenheim Partners, Pomerantz, Defendant, NASH, LLP, Court, Action Replay, Weight loss, District court, Bloomberg, Complaint

To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (“MASH”).
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, Altimmune, and UnitedHealth and Encourages Investors to Contact the Firm

Retrieved on: 
日曜日, 5月 26, 2024
Insurance, Semaglutide, EQIX, UNH, UnitedHealth Group, Partnership, The Wall Street Journal, MASH, Hepatology, Optum, Kerrisdale, News, Obesity, CSI, Change Healthcare, Guggenheim Partners, OTC, Defendant, NASH, Policy, Acquisition, P.C, Weight loss, DOJ, Bloomberg, Disclosure, Complaint

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR

Key Points: 
  • For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
    Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
  • The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
  • On January 6, 2021, UnitedHealth announced an agreement to acquire Change Healthcare (“Change”) and integrate it into its Optum business.
  • As a result of this disclosure, the price of UnitedHealth stock declined by $27 per share, erasing nearly $25 billion in shareholder value.

ALT Stockholders: Robbins LLP Reminds ALT Stockholders of Securities Fraud Class Action Against Altimmune, Inc.

Retrieved on: 
木曜日, 5月 23, 2024
Partnership, Hepatology, News, ALT, Viability, Obesity, SAN, Person, Efficacy, Complaint, LLP, Weight loss, Bloomberg, Pharmaceutical industry

SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024.

Key Points: 
  • SAN DIEGO, May 23, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Altimmune, Inc. (NASDAQ: ALT) securities between December 1, 2023 and April 26, 2024.
  • The Company’s lead product candidate is pemvidutide, a glucagon-like peptide-1 (“GLP-1”) agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.
  • For more information, submit a form , email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

Retrieved on: 
水曜日, 5月 22, 2024
Patient, MASH, EASL, University, SAN, Congress, Division, FGF21, Fibrosis, Hepatology, Pharmaceutical industry

SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented in an oral and poster presentation at the European Association for the Study of the Liver (EASL) Congress to be held June 5 to 8, 2024 in Milan, Italy.

Key Points: 
  • SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented in an oral and poster presentation at the European Association for the Study of the Liver (EASL) Congress to be held June 5 to 8, 2024 in Milan, Italy.
  • “These data, which are being presented for the first time in a scientific setting, establish pegozafermin as the first FGF21 analog candidate to demonstrate positive, sustained benefits over a 48-week period in patients with advanced MASH,” said Hank Mansbach, Chief Medical Officer of 89bio.
  • “In addition, these data highlight the observed long-term efficacy, tolerability and sustained improvement in key liver health markers, that we aim to confirm in our ongoing Phase 3 program.”
    Presentation details are as follows:
    Presenting Author: Rohit Loomba, M.D., MHSc, Chief of the Division of Gastroenterology and Hepatology at University of California San Diego School of Medicine, and lead investigator of the ENLIGHTEN program

Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024

Retrieved on: 
水曜日, 5月 22, 2024
University of Hong Kong, Doctor of Philosophy, Doctor of Science, EASL, Congress, University, Therapy, FRCP, SAN, Division, Abstract, MBBS, MRCP, Hepatology

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced six abstracts have been accepted for poster presentations, including two Top abstracts, at the European Association for the Study of the Liver (EASL) Congress 2024, being held June 5-8 in Milan, Italy.
  • The abstracts released today can be found on the EASL website at www.easlcongress.eu .
  • Details from the abstracts released today are as follows:
    Presenter: Professor Man-Fung Yuen, MBBS, MD, PhD, DSc, Chair and Chief of the Division of Gastroenterology and Hepatology, University of Hong Kong
    Presenter: Kosh Agarwal, MBBS, MRCP (UK), MD, FRCP (Ed), FRCP (London), Consultant Hepatologist and Transplant Physician, Institute of liver Studies, King’s College Hospital NHS Foundation Trust
    Abstracts identified as “Top” were selected as among the best in their category.
  • These posters will be displayed during the four days of the congress.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Equinix, Harbor Diversified, and Altimmune and Encourages Investors to Contact the Firm

Retrieved on: 
水曜日, 5月 22, 2024
Semaglutide, EQIX, Partnership, MASH, Hepatology, Kerrisdale, News, Obesity, Guggenheim Partners, OTC, Defendant, NASH, P.C, Weight loss, Bloomberg, Complaint

For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR

Key Points: 
  • For more information on the Harbor Diversified class action go to: https://bespc.com/cases/HRBR
    Altimmune is a clinical stage biopharmaceutical company that focuses on developing treatments for obesity and liver diseases.
  • The Company's lead product candidate is pemvidutide, a glucagon-like peptide-1 ("GLP-1") agonist for the treatment of obesity and metabolic dysfunction-associated steatohepatitis ("MASH").
  • On this news, Altimmune's stock price fell $0.87 per share, or 11.98%, to close at $6.39 per share on April 29, 2024.
  • For more information on the Altimmune class action go to: https://bespc.com/cases/ALT